Lifeboat Foundation

A protein-secreting device implanted into the hippocampus of epileptic rats reduces seizures by 93 percent in three months, finds preclinical research published in JNeurosci. These results support ongoing development of this technology and its potential translation into a new treatment for epilepsy.

Motivated by an unmet need for effective and well-tolerated epilepsy therapies, Giovanna Paolone and colleagues of the University of Ferrara, Italy and of Gloriana Therapeutics, Inc. (Providence, RI) investigated the effects of the Gloriana targeted cellular delivery system for glial cell line-derived neurotrophic factor (GDNF)—a protein recent research suggests may help suppress epileptic activity.

In addition to quickly and progressively reducing seizures in male rats—by 75 percent within two weeks—the researchers found their device improved rats’ anxiety-like symptoms and their performance on an object recognition task, indicating improvement in cognition.

Continue reading “Implantable device curbs seizures and improves cognition in epileptic rats” »

According to the World Health Organisation, up to a half-million people around the world suffer a spinal cord injury each year. Often caused by road traffic crashes, accidents or violence, the loss of motor control or paralysis significantly impacts quality of life and requires years of treatment and care. Spinal cord injury is also associated with lower rates of school enrollment and economic participation, and carries substantial individual and societal costs.

Current methods for spinal cord injury treatment involve cumbersome brain-machine interfaces, with many cables linking the patient and a computer to restore limited motor functions. Other methods to map brain activity, such as magnetoencephalography, require very large machinery and particularly low-temperature working conditions.

Continue reading “Can nanotechnology rewire an injured spinal cord?” »

The piezoelectric materials that inhabit everything from our cell phones to musical greeting cards may be getting an upgrade thanks to work discussed in the journal Nature Materials released online Jan 21.

Immune cells called macrophages are supposed to serve and protect, but cancer has found ways to put them to sleep. Now researchers at the Abramson Cancer Center of the University of Pennsylvania say they’ve identified how to fuel macrophages with the energy needed to attack and eat cancer cells. It is well established that macrophages can either support cancer cell growth and spread or hinder it. But most tumors also express a signal called CD47, which can lull macrophages into a deep sleep and prevent them from eating. Researchers have found that rewiring macrophage metabolism can overcome this signal and act like an alarm clock to rouse and prepare macrophages to go to work. Their findings were published in Nature Immunology today.

Macrophages are immune cells just like T and B cells, but differ in that they can eat cells that are not supposed to be in the body. In fact, they are the most prominent immune cell found in cancer, but unfortunately, most are often convinced to help cancer grow and spread. Cancer cells frequently stop macrophages from attacking them by expressing CD47, a “don’t eat me” signal. Researchers now say that merely blocking inhibitory signals like CD47 is not always sufficient to convince macrophages to attack cancer. Instead, two signals are required. First, they need a signal to activate them—such as a toll-like receptor agonist. After that, a second signal—such as a CD47 inhibitor—can lower the threshold needed to wage battle on the cancer.

“It turns out macrophages need to be primed before they can go to work, which explains why solid tumors may resist treatment with CD47 inhibitors alone,” said the study’s senior author Gregory L. Beatty, MD, Ph.D., an assistant professor of Hematology-Oncology at Penn’s Perelman School of Medicine. Jason Mingen Liu, an MD and Ph.D. graduate student in Beatty’s lab, is the study’s lead author.

A fascinating study from researchers at the University of Basel has revealed a method that forces malignant breast cancer cells to turn into fat cells. The research, currently only demonstrated in mice, suggests the process could stop tumors from metastasizing and potentially make the cancer more susceptible to conventional chemotherapy.

Scientists from global biopharmaceutical company MSD will come to the Crick next year to tackle a range of conditions associated with ageing such as dementia and Parkinson’s disease.

A new team of around 15 MSD chemists and pharmacologists will be based at the Crick over the next five years, working to develop new understandings of diseases that affect the UK’s ageing population.

The scientists will be based at the Crick while MSD establishes their new discovery science centre and UK headquarters in London, the location of which is being finalised. Their work will complement the MSD neuroscience cell biology team already established at the London Bioscience Innovation Centre, and both teams will eventually move to MSD’s new centre.

Continue reading “MSD scientists to tackle diseases of ageing at the Crick” »

Read more

TAE Technologies has also looked at building a nuclear fusion rocket. Nextbigfuture had covered TAE Technologies recent announcement that they will have a commercial nuclear fusion rocket by 2023.

The AIP Conference Proceedings 2004 – Colliding Beam Fusion Reactor Space Propulsion System

The Colliding Beam Fusion Reactor (CBFR( requires approximately 50 MW of injected power for steady-state operation. The H-B11 CBFR would generate approximately 77 MW of nuclear (particle) power, half of which is recovered in the direct-energy converter with 90% efficiency. An additional 11.5 MW are needed to sustain the reactor which is provided by the thermo-electric converter and Brayton-heat engine. The principal source of heat in the CBFR-SPS is due to Bremstrahlung radiation. The thermo-electric converter recovers approximately 20% of the radiation, or 4.6 MW, transferring approximately 18.2 MW to the closed-cycle, Brayton-heat engine.

Continue reading “If TAE Technologies Succeeds With Commercial Fusion Then a Fusion Rocket Will Follow” »